Kairos Pharma Statistics
Total Valuation
Kairos Pharma has a market cap or net worth of $2.95 million. The enterprise value is $319,136.
| Market Cap | 2.95M |
| Enterprise Value | 319,136 |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kairos Pharma has 3.39 million shares outstanding. The number of shares has increased by 46.73% in one year.
| Current Share Class | 3.39M |
| Shares Outstanding | 3.39M |
| Shares Change (YoY) | +46.73% |
| Shares Change (QoQ) | +1.95% |
| Owned by Insiders (%) | 28.80% |
| Owned by Institutions (%) | 7.82% |
| Float | 2.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.98
| Current Ratio | 11.98 |
| Quick Ratio | 9.91 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -113.96% and return on invested capital (ROIC) is -73.09%.
| Return on Equity (ROE) | -113.96% |
| Return on Assets (ROA) | -66.91% |
| Return on Invested Capital (ROIC) | -73.09% |
| Return on Capital Employed (ROCE) | -142.14% |
| Weighted Average Cost of Capital (WACC) | 12.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.45M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.81% in the last 52 weeks. The beta is 1.45, so Kairos Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.45 |
| 52-Week Price Change | -89.81% |
| 50-Day Moving Average | 1.90 |
| 200-Day Moving Average | 3.47 |
| Relative Strength Index (RSI) | 17.11 |
| Average Volume (20 Days) | 612,509 |
Short Selling Information
The latest short interest is 114,388, so 3.38% of the outstanding shares have been sold short.
| Short Interest | 114,388 |
| Short Previous Month | 52,035 |
| Short % of Shares Out | 3.38% |
| Short % of Float | 5.09% |
| Short Ratio (days to cover) | 1.40 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.96M |
| Pretax Income | -5.81M |
| Net Income | -5.81M |
| EBITDA | -5.82M |
| EBIT | -5.96M |
| Earnings Per Share (EPS) | -$1.95 |
Balance Sheet
The company has $2.63 million in cash and no debt, with a net cash position of $2.63 million or $0.78 per share.
| Cash & Cash Equivalents | 2.63M |
| Total Debt | n/a |
| Net Cash | 2.63M |
| Net Cash Per Share | $0.78 |
| Equity (Book Value) | 4.19M |
| Book Value Per Share | 1.37 |
| Working Capital | 2.91M |
Cash Flow
| Operating Cash Flow | -3.97M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 142,000 |
| Net Borrowing | 3.38M |
| Free Cash Flow | -3.97M |
| FCF Per Share | -$1.17 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kairos Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -46.73% |
| Shareholder Yield | -46.73% |
| Earnings Yield | -197.10% |
| FCF Yield | -134.80% |
Analyst Forecast
The average price target for Kairos Pharma is $49.00, which is 5,532.18% higher than the current price. The consensus rating is "Buy".
| Price Target | $49.00 |
| Price Target Difference | 5,532.18% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 1, 2026. It was a reverse split with a ratio of 1:7.
| Last Split Date | Sep 1, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |